Case Review Form

      * Denotes required field.


      * First Name

      * Last Name

      * Email Address

      * Phone Number

      Cell Phone Number

      Office Phone Number

      Street Address




      Zip Code

      Please provide the best method and times to contact you:

      Date of birth of injured person

      Name of drug:

      Date you started taking the drug (mm-yyyy):

      Date you stopped taking the drug (mm-yyyy):

      Please describe any side effects:

      Other Info:

      No Yes, I agree to the Parker & Waichman LLP disclaimers.Click here to review all.

      Yes, I would like to receive the Parker & Waichman LLP monthly newsletter, InjuryAlert.

      please do not fill out the field below.

Migraine With Aura, Combined Hormone Birth Control Linked to Thrombotic Events

Filed February 11th, 2013 admin

Migraine with aura is associated with an elevated risk for thrombotic complications in women who use combined hormonal contraceptives (CHCs), such as Yaz and Yasmin, a new study revealed.

The risk appears to be highest with newer agents, such as Yaz and Yasmin, said. Researchers opened the study to look at whether or not newer versus older combined hormonal contraceptives increased thrombotic events. They also wanted to see whether migraine with aura has an additive component for thrombotic risk factors, said.

Lead author Dr. Shivang Joshi and his colleagues used a computerized patient database from the Research Patient Data Registry of Partners Healthcare to identify patients who were diagnosed with migraine with and without aura between 2001 and 2012. The researchers looked at the outcome of deep-vein thrombosis (DVT), pulmonary embolism, myocardial infarction (MI), transient ischemic attack, and ischemic stroke among 145,304 women, medscape said.

All of the study participants were taking one of the newer CHCs or an older contraceptive agent. According to preliminary data analysis, an overall trend revealed that the greatest risk for thrombotic events was in women with migraine with aura versus migraine without aura, followed by migraine with aura versus no migraine, said. The researchers also found that the risk for a thrombotic event in women with migraine appeared to be greatest with the newer agents. For example, DVT was diagnosed in 7.6 percent of women with migraine who used Yaz (drospirenone) compared with 6.3 percent of women with migraine without aura, said. The study results are scheduled to be presented in March during the American Academy of Neurology 65th Annual Meeting in San Diego, California.

Be Sociable, Share!

Comments are closed.

Click Here Now, to Have an Attorney Answer Your
Medicinal Drug Injuries Questions
No Cost - No Obligation!